International Medical Center of Biomaterials Processing and Cryostorage (MOEX:GEMA)
Russia · Delayed Price · Currency is RUB 672.00
-1.50 (-0.22%)
At close: Jul 8, 2022
MOEX:GEMA Income Statement
Financials in millions RUB. Fiscal year is January - December.
Millions RUB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 390.61 | 376.74 | 348.6 | 283.51 | 254.68 | 265.89 | |
Revenue Growth | 4.91% | 8.07% | 22.96% | 11.32% | -4.22% | 9.59% |
Cost of Revenue | 82 | 72.7 | 58.72 | 47.95 | 51.67 | 61.82 |
Gross Profit | 308.6 | 304.04 | 289.89 | 235.56 | 203 | 204.07 |
Selling, General & Admin | 135.83 | 122.24 | 111.74 | 86.2 | 64.41 | 65.52 |
Operating Expenses | 135.83 | 122.24 | 111.74 | 86.2 | 64.41 | 66.17 |
Operating Income | 172.78 | 181.8 | 178.15 | 149.36 | 138.6 | 137.9 |
Interest Expense | -34.53 | -34.53 | -34.57 | -33.56 | -17.62 | -3.52 |
Interest & Investment Income | 27.97 | 27.88 | 23.85 | 11.98 | 10.54 | 17.48 |
Earnings From Equity Investments | 9 | - | 9 | 6.53 | - | - |
Currency Exchange Gain (Loss) | 0.02 | 0.02 | 0.03 | - | - | - |
Other Non Operating Income (Expenses) | -47.21 | -19.45 | -24.11 | -8.73 | -32 | -18.7 |
EBT Excluding Unusual Items | 128.02 | 155.72 | 152.36 | 125.58 | 99.52 | 133.17 |
Gain (Loss) on Sale of Assets | -0.1 | -0.1 | -3.43 | 0.2 | -1.35 | -4 |
Other Unusual Items | 2.77 | 2.77 | 2.29 | - | - | - |
Pretax Income | 130.69 | 158.39 | 151.22 | 125.78 | 98.17 | 129.17 |
Net Income | 130.69 | 158.39 | 151.22 | 125.78 | 98.17 | 129.17 |
Preferred Dividends & Other Adjustments | - | - | - | - | - | -21.57 |
Net Income to Common | 130.69 | 158.39 | 151.22 | 125.78 | 98.17 | 150.74 |
Net Income Growth | -16.37% | 4.74% | 20.22% | 28.13% | -34.88% | 22.78% |
Shares Outstanding (Basic) | 17 | 15 | 15 | 15 | 15 | 15 |
Shares Outstanding (Diluted) | 17 | 15 | 15 | 15 | 15 | 15 |
Shares Change | 17.01% | 0.00% | -0.02% | - | -0.00% | 0.00% |
EPS (Basic) | 7.48 | 10.61 | 10.13 | 8.42 | 6.58 | 10.10 |
EPS (Diluted) | 7.48 | 10.61 | 10.13 | 8.42 | 6.58 | 10.10 |
EPS Growth | -28.52% | 4.74% | 20.24% | 28.13% | -34.88% | 22.79% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 151.43 | 204.55 | 237.02 | 209.59 | 231.83 | 239.82 |
Free Cash Flow Per Share | 8.67 | 13.70 | 15.88 | 14.04 | 15.53 | 16.06 |
Dividend Per Share | 10.800 | 10.800 | 10.100 | 6.420 | 8.022 | 8.650 |
Dividend Growth | 350.00% | 6.93% | 57.32% | -19.97% | -7.26% | - |
Gross Margin | 79.01% | 80.70% | 83.16% | 83.09% | 79.71% | 76.75% |
Operating Margin | 44.23% | 48.26% | 51.10% | 52.68% | 54.42% | 51.86% |
Profit Margin | 33.46% | 42.04% | 43.38% | 44.37% | 38.55% | 56.69% |
Free Cash Flow Margin | 38.77% | 54.30% | 67.99% | 73.93% | 91.03% | 90.20% |
EBITDA | 183.12 | 191.51 | 187.01 | 157.64 | 142.41 | 142.04 |
EBITDA Margin | 46.88% | 50.83% | 53.64% | 55.60% | 55.92% | 53.42% |
D&A For EBITDA | 10.34 | 9.71 | 8.86 | 8.28 | 3.81 | 4.14 |
EBIT | 172.78 | 181.8 | 178.15 | 149.36 | 138.6 | 137.9 |
EBIT Margin | 44.23% | 48.26% | 51.10% | 52.68% | 54.42% | 51.86% |
Advertising Expenses | - | 38.14 | 28.32 | 23.97 | 17.11 | 15.86 |